NASDAQ: KROS

US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept. Elritercept’s Clinical Studies and IndicationsElritercept is currently the subject of two clinical studies, one focusing on myelodysplastic syndromes (MDS) and…